Atezolizumab + intravesical BCG (Bacillus Calmette-Guerin) in high-risk non-muscle invasive bladder cancer (NMIBC) patients: Institutional clinical and translational study (BladderGATE).

Daniel Castellano,Guillermo Velasco,Maria Cruz Martin Soberón,Alberto Carretero-González,Marta Dueñas,Jesús M. Paramio,Federico de la Rosa,Juan-Luis Sanz,Felix Guerrero

Atezolizumab + intravesical BCG (Bacillus Calmette-Guerin) in high-risk non-muscle invasive bladder cancer (NMIBC) patients: Institutional clinical and translational study (BladderGATE).

2020

Daniel Castellano
Guillermo Velasco
Maria Cruz Martin Soberón
Alberto Carretero-González
Marta Dueñas
Jesús M. Paramio
Federico de la Rosa
Juan-Luis Sanz
Felix Guerrero

TPS598Background: Intravesical Bacillus Calmette-Guerin (BCG) induction + BCG maintenance after transurethral resection (TURBT) is the current standard of care for patients (pt) with high-risk non-...

Keywords:

Atezolizumab
Urology
Resection
Pathology
Intravesical bcg
standard of care
Bladder cancer
Medicine
non muscle invasive

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations